PepGen Past Earnings Performance
Past criteria checks 0/6
PepGen's earnings have been declining at an average annual rate of -44.4%, while the Biotechs industry saw earnings growing at 19.3% annually.
Key information
-44.4%
Earnings growth rate
29.0%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -63.5% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Here's Why We're Watching PepGen's (NASDAQ:PEPG) Cash Burn Situation
Nov 19
PepGen (NASDAQ:PEPG) Is In A Good Position To Deliver On Growth Plans
Aug 06PepGen: EDOs Could Enhance Dystrophin Expression Beyond Scope Of Current Treatments
Jul 31The Prognosis For PepGen
May 20PepGen: Long Road Ahead
Jan 20Will PepGen (NASDAQ:PEPG) Spend Its Cash Wisely?
Nov 13Will PepGen (NASDAQ:PEPG) Spend Its Cash Wisely?
Jul 31We Think PepGen (NASDAQ:PEPG) Can Afford To Drive Business Growth
Dec 31Here's Why We're Not Too Worried About PepGen's (NASDAQ:PEPG) Cash Burn Situation
Sep 07PepGen GAAP EPS of -$1.23 misses by $0.47
Aug 12Revenue & Expenses Breakdown
How PepGen makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -87 | 20 | 74 |
| 30 Jun 24 | 0 | -89 | 19 | 77 |
| 31 Mar 24 | 0 | -80 | 18 | 68 |
| 31 Dec 23 | 0 | -79 | 17 | 68 |
| 30 Sep 23 | 0 | -74 | 16 | 65 |
| 30 Jun 23 | 0 | -69 | 16 | 60 |
| 31 Mar 23 | 0 | -67 | 15 | 58 |
| 31 Dec 22 | 0 | -69 | 14 | 54 |
| 30 Sep 22 | 0 | -61 | 13 | 45 |
| 30 Jun 22 | 0 | -51 | 12 | 35 |
| 31 Mar 22 | 0 | -39 | 10 | 24 |
| 31 Dec 21 | 0 | -27 | 8 | 19 |
| 30 Sep 21 | 0 | -23 | 6 | 15 |
| 30 Jun 21 | 0 | -15 | 4 | 9 |
| 31 Mar 21 | 0 | -10 | 2 | 6 |
| 31 Dec 20 | 0 | -4 | 1 | 1 |
Quality Earnings: PEPG is currently unprofitable.
Growing Profit Margin: PEPG is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PEPG is unprofitable, and losses have increased over the past 5 years at a rate of 44.4% per year.
Accelerating Growth: Unable to compare PEPG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PEPG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: PEPG has a negative Return on Equity (-63.46%), as it is currently unprofitable.